Bina Technologies and AstraZeneca Announce Collaborative Agreement for Global Deployment of Bina’s Genomic Management Solut...
April 21 2015 - 7:00AM
Business Wire
AstraZeneca will use Bina’s Genomic Management Solution to
accelerate the incorporation of genomic data into its drug
development programs across three main therapeutic areas
Bina Technologies, Inc., a member of the Roche Group (SIX:
RO, ROG; OTCQX: RHHBY), and AstraZeneca (NYSE: AZN) today announced
that they have entered into an agreement for AstraZeneca to become
the first member to join the Bina Alliance Program and to further
develop the Bina Genomic Management Solution (GMS)1.
AstraZeneca will utilize the Bina GMS as an enterprise platform to
support its development work across three main therapeutic areas:
oncology, cardiovascular and metabolic disease, and respiratory,
inflammation and autoimmunity.
Bina’s proprietary technology enables translational and academic
researchers to perform fast and scalable analyses to maximize the
value of genomic data. Under the terms of the agreement,
AstraZeneca will adopt Bina GMS globally to support enterprise
genomic data analysis and management. Bina in turn will provide
AstraZeneca with direct access to its scientific and engineering
teams to further develop the Bina GMS for pharmaceutical
applications.
Dr. Carl Barrett, Vice President, Translational Oncology, at
AstraZeneca, said: “Bina GMS is a powerful data analysis platform
that will help AstraZeneca leverage more effectively genomic data
across all phases of our research globally as we develop
personalized therapies to treat complex diseases.”
Justin Johnson, Principal Translational Genomic Scientist at
AstraZeneca, added: “In working with Bina, we can not only
significantly accelerate the speed in which we incorporate genomic
data into areas like target discovery and patient selection, but we
can do this on top of a flexible, scalable and validated
analysis infrastructure that our bench scientists can work with.”
Johnson will be presenting early results of the collaboration
during the Cambridge Healthtech Institute’s 14th Annual Bio-IT
World Conference and Expo (Bio-IT) in Boston, MA on Thursday 23
April.
“We are very excited about the work we are doing with the
AstraZeneca team,” said Dr. Narges Bani Asadi, CEO and Founder of
Bina. “In this collaboration, our multidisciplinary team of
scientists and engineers will try to push the boundaries of
genomics research. We are very fortunate to be able to contribute
to the research at AstraZeneca. Through this collaboration we both
hope to define a new standard for the pharmaceutical research
industry in how to effectively leverage the genomic information for
discovery and development.”
For more information on the Bina Alliance Program, please
contact bizdev@bina.com. Academic researchers please visit the
Bina Research Grant Program.
1 Bina products are for research use only and not for use in
diagnostic procedures.
About Bina Technologies
Bina Technologies builds next-generation technologies for
scalable, accurate processing and management of genomic
information. Bina’s Genomic Management Solution is a comprehensive
analysis platform used by clinical and translational researchers to
gain insight from their genomic data sets. Bina’s Genomic
Management Solution dramatically decreases the complexity, time,
and cost of genomic analysis, accelerating the science of
personalized medicine. Bina Technologies was acquired by Roche in
December, 2014. Learn more about Bina’s product, technologies, and
team at www.bina.com.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in
research-focused healthcare with combined strengths in
pharmaceuticals and diagnostics. Roche is the world’s largest
biotech company, with truly differentiated medicines in oncology,
immunology, infectious diseases, ophthalmology and neuroscience.
Roche is also the world leader in in vitro diagnostics and
tissue-based cancer diagnostics, and a frontrunner in diabetes
management. Roche’s personalised healthcare strategy aims at
providing medicines and diagnostics that enable tangible
improvements in the health, quality of life and survival of
patients. Founded in 1896, Roche has been making important
contributions to global health for more than a century. Twenty-four
medicines developed by Roche are included in the World Health
Organisation Model Lists of Essential Medicines, among them
life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide,
invested 8.7 billion Swiss francs in R&D and posted sales of
46.8 billion Swiss francs. Genentech, in the United States, is a
wholly owned member of the Roche Group. Roche is the majority
shareholder in Chugai Pharmaceutical, Japan. For more information,
please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical
business that focuses on the discovery, development and
commercialisation of prescription medicines, primarily for the
treatment of cardiovascular, metabolic, respiratory, inflammation,
autoimmune, oncology, infection and neuroscience diseases.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more
information please visit: www.astrazeneca.com
Bina Technologies Media EnquiriesChempetitive Group for
BinaKena Hudson or Rachel
Wallace510-908-0966BinaTeam@Chempetitive.comorRoche Sequencing
Media EnquiriesRoche Sequencing Media RelationsJacquie Bucher,
520-468-9145jacquie.bucher@ventana.roche.comorAstraZeneca
EnquiriesEsra Erkal-Paler, +44 20 7604 8030Ayesha Bharmal, +44
20 7604 8034
Rocky Old Man Energy (TSXV:RO)
Historical Stock Chart
From Apr 2024 to May 2024
Rocky Old Man Energy (TSXV:RO)
Historical Stock Chart
From May 2023 to May 2024